Charm is using deep-learning models via its proprietary platform, DragonFold, to predict the co-crystal structure of a protein-ligand complex based on a protein's primary sequence and the ligand’s chemical structure.
Charm Therapeutics has raised €116M across 2 funding rounds from 9 investors, most recently a Series B round in Sep 2025. Based in London, UK; active in AI. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-09-02 | Series B | €69M | F-Prime Capital,Khosla Ventures,New Enterprise Associates (NEA),NVIDIA,OrbiMed,SR One | View deal → |
| 2022-06-10 | Series A | €47M | Axial,Braavos Capital,F-Prime Capital,General Catalyst,Khosla Ventures,OrbiMed | View deal → |
